Phathom Pharmaceuticals (PHAT) Retained Earnings (2022 - 2025)
Historic Retained Earnings for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$1.5 billion.
- Phathom Pharmaceuticals' Retained Earnings fell 2309.94% to -$1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year decrease of 2309.94%. This contributed to the annual value of -$1.3 billion for FY2024, which is 3599.99% down from last year.
- Per Phathom Pharmaceuticals' latest filing, its Retained Earnings stood at -$1.5 billion for Q3 2025, which was down 2309.94% from -$1.4 billion recorded in Q2 2025.
- Phathom Pharmaceuticals' Retained Earnings' 5-year high stood at -$570.0 million during Q1 2022, with a 5-year trough of -$1.5 billion in Q3 2025.
- Its 4-year average for Retained Earnings is -$983.9 million, with a median of -$928.7 million in 2023.
- In the last 5 years, Phathom Pharmaceuticals' Retained Earnings plummeted by 3997.63% in 2024 and then crashed by 2309.94% in 2025.
- Over the past 4 years, Phathom Pharmaceuticals' Retained Earnings (Quarter) stood at -$727.1 million in 2022, then dropped by 27.73% to -$928.7 million in 2023, then tumbled by 36.0% to -$1.3 billion in 2024, then decreased by 15.84% to -$1.5 billion in 2025.
- Its Retained Earnings was -$1.5 billion in Q3 2025, compared to -$1.4 billion in Q2 2025 and -$1.4 billion in Q1 2025.